Since the quarter ended December 31st, 2008, Thermo Fisher Scientific Inc's accounts receivable has increased from $1.48 Billion to $7.94 Billion as of the quarter ended June 29th, 2024.
Thermo Fisher Scientific Inc's accounts receivable during the quarter ended June 29th, 2024 of $7.94 Billion was higher than its peers in the Medical Laboratories & Research industry group during the quarter ended June 30th, 2024 of 322 Million. From December 31st, 2008 to June 29th, 2024, Thermo Fisher Scientific Inc's average accounts receivable was 3.9 Billion compared to an industry average of 283 Million.
Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. The company operates its business through four segments: Analytical Technologies, Specialty Diagnostics, Life Sciences Solutions and Laboratory Products and Services. The Analytical Technologies segment is engaged in instruments, reagents, consumables, software and services that are used for applications in the laboratory on the production line and in the field. The Specialty Diagnostics segment offers diagnostic test kits, reagents, culture media, instruments and associated products in order to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The Life Sciences Solutions segment enable, simplify and accelerate a broad spectrum of biological research of genes, proteins and cells within academic and life science research, clinical research and commercial applications. The Laboratory Products and Services segment offers virtually everything needed for the laboratory. Thermo Fisher Scientific was founded in November 2006 and is headquartered in Waltham, MA
© 2021 DiscoverCI
Disclaimer: DiscoverCI LLC is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on DiscoverCI.com represent a recommendation to buy or sell a security. The information on this site, and in its related application software, spreadsheets, blog, email and newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. In no event shall DiscoverCI.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any product, content or other material published or available on DiscoverCI.com, or relating to the use of, or inability to use, DiscoverCI.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related blog, email and newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way.